Introduction
Neurodegenerative diseases are characterized by progressive and often irreversible degeneration of cells within the central nervous system (CNS). While these conditions primarily affect older adults, some forms, like variant Creutzfeldt-Jakob disease (CJD), multiple sclerosis (MS), and HIV-associated neurocognitive disorder (HAND) can also impact younger individuals. These disorders exhibit diverse clinical presentations and underlying causes, making accurate diagnosis challenging. Neuroimaging biomarkers have emerged as valuable tools for aiding clinical diagnosis and monitoring disease progression across a range of neurodegenerative disorders. This article will explore various neuroimaging biomarkers and their role in the early detection and prognosis of neurodegenerative diseases.
What Are the Neuroimaging Biomarkers of Neurodegenerative Diseases?
Biomarkers for neurodegenerative diseases are crucial indicators that aid in identifying, tracking, diagnosing, and monitoring these conditions. Neuroimaging techniques play a significant role in providing such biomarkers. The three primary neuroimaging methods used are magnetic resonance imaging (MRI) and radionucleotide imaging (including single-photon emission computerized tomography [SPECT] and positron emission tomography [PET]). These biomarkers are discussed below.
-
Structural MRI: Unveiling Anatomical Changes and Neurodegeneration:
Structural MRI emerges as a pivotal technique to study anatomical alterations and neurodegeneration in vivo. It enables the examination of both global and local brain atrophy. Furthermore, advanced variations of structural MRI, encompassing diffusion-weighted and diffusion tensor imaging (DWI/DTI), magnetic resonance spectroscopy (MRS), and perfusion imaging, find applications in dementia research.
-
DWI/DTI: Assessing Tissue Integrity:
DWI/DTI techniques play a crucial role in assessing tissue integrity. Fractional anisotropy (FA) and mean diffusivity (MD) or apparent diffusion coefficient (ADC) serve as measures for neuronal fiber loss and reduced gray and white matter integrity. Altered FA and increased MD/ADC values are indicative of these structural changes.
-
MRS: Unveiling Neurochemical Insights:
Magnetic resonance spectroscopy (MRS) presents a noninvasive approach to uncover neurochemical insights. It measures metabolite levels within target tissues. In dementia studies, notable alterations in N-acetyl aspartate (NAA) and myo-inositol (mIns) are observed. NAA reflects neuronal integrity, while mIns indicate glial cell proliferation and neuronal damage. Other MRS analytes also contribute valuable information about membrane integrity and metabolism.
-
Cerebral Perfusion:
The assessment of cerebral perfusion holds significance in the study of neurodegeneration and dementia. Techniques such as dynamic susceptibility contrast-enhanced MRI, arterial spin labeling (ASL), SPECT, and PET provide insights into blood flow dynamics within the brain, offering valuable information about perfusion changes in these conditions.
-
Functional MRI (fMRI):
Functional MRI (fMRI) is employed to analyze brain activity during cognitive tasks or at rest. By evaluating blood flow and oxygen levels, the blood oxygenation level-dependent (BOLD) contrast signal is utilized to measure brain activation. However, in cases of altered coupling between neuronal metabolism and blood flow, brain atrophy, or hypoperfusion, the BOLD signal might be affected. Brain connectivity, studied through fMRI data, provides insights into brain network activity both during tasks and in the resting state.
-
PET and SPECT:
Positron emission tomography (PET) and single-photon emission computerized tomography (SPECT) rely on radiolabeled ligands to provide functional insights. PET employs various tracers, including [18F] fluorodeoxyglucose (FDG) for glucose metabolism, ligands for protein deposits (e.g., amyloid deposition), neurotransmitter system assessment, and activated microglia measurement. These techniques offer valuable data about functional changes, protein levels, and brain metabolism, which are crucial for understanding degenerative changes within the brain.
What Is the Role of Neuroimaging Biomarkers for Neurodegenerative Diseases?
The role of neuroimaging biomarkers for neurodegenerative diseases is pivotal in enhancing diagnostic accuracy, tracking disease progression, and providing insights into underlying pathophysiology. Neuroimaging techniques such as magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), positron emission tomography (PET), dopamine transporter imaging (DAT Imaging), and amyloid and tau imaging play a crucial role in this regard.
-
Magnetic Resonance Imaging (MRI):
MRI serves as a diagnostic tool for neurodegenerative diseases such as Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and progressive supranuclear palsy (PSP). Characteristic MRI findings are recognized as biomarkers in certain diagnostic criteria. For instance, the NIA-AA guidelines for AD emphasize disproportionate atrophy in specific brain regions as a biomarker of neuronal degeneration. DLB diagnostic criteria mention the absence of medial temporal lobe atrophy as a supportive biomarker, aiding in differentiation from other conditions. PSP guidelines highlight midbrain atrophy relative to the pons as a supportive feature. While MRI is vital for assessing structural changes, it also plays a role in functional evaluation through techniques like functional MRI (fMRI) and diffusion tensor imaging (DTI).
-
SPECT and PET Imaging:
SPECT and PET imaging techniques, utilizing radiolabeled ligands, provide insights into metabolic, neurochemical, and perfusion processes. In AD, reduced 18 fluorodeoxyglucose (FDG) uptake on PET in specific brain regions is indicative of neuronal degeneration. DLB diagnostic guidelines describe hypoperfusion/hypometabolism by SPECT/PET in certain brain areas as supportive biomarkers. DAT imaging with SPECT or PET is valuable for differentiating DLB from other dementias. These techniques aid in detecting abnormal myocardial scintigraphy, offering insights into sympathetic cardiac denervation in Lewy body diseases and Parkinson's disease.
-
Iodine-Metaiodobenzylguanidine Myocardial Scintigraphy (MIBG):
MIBG Myocardial Scintigraphy is an essential tool, particularly for conditions associated with cardiac sympathetic denervation, such as Lewy body diseases and Parkinson's disease. This technique offers insights into adrenergic dysfunction, highlighting abnormal myocardial scintigraphy. MIBG myocardial scintigraphy is recognized as an indicative biomarker in the latest diagnostic criteria for dementia with Lewy bodies (DLB). It provides an accurate method for distinguishing between probable DLB and other dementias, offering improved sensitivity and specificity in the assessment.
-
Dopamine Transporter Imaging (DAT Imaging):
DAT Imaging, utilizing SPECT or PET with ligands binding to the presynaptic dopamine transporter, is crucial for assessing the integrity of the nigrostriatal projection pathway. It aids in diagnosing conditions related to dopamine dysfunction, such as Parkinson's syndrome and associated disorders. Reduced DAT uptake is observed in conditions like Parkinson's disease (PD), indicating dysfunction of the nigrostriatal projection pathway. However, DAT imaging is not suitable for differentiating between various presynaptic Parkinson's syndromes. The diagnostic criteria for PD do not mention DAT imaging as a biomarker, primarily due to its limitations and potential confounding factors like medication effects. Nonetheless, DAT imaging is crucial in distinguishing dementia with Lewy bodies (DLB) from other dementias, with reduced uptake in the basal ganglia as a well-established indicative biomarker.
-
Amyloid and Tau Imaging:
Amyloid imaging using PET tracers provides valuable information about Aβ protein deposition, aiding in the diagnosis of AD. Low CSF Aβ42 and positive PET amyloid imaging are indicative biomarkers of brain Aβ protein deposition. Tau imaging, utilizing PET tracers, is a promising avenue for detecting tau pathology related to neurodegeneration. Though tau imaging is not yet formally recognized as a biomarker in diagnostic criteria, it holds the potential for identifying tau-specific changes in various tauopathies.
Conclusion
In conclusion, neuroimaging techniques such as MRI, PET, SPECT, and others serve as multifaceted biomarkers for neurodegenerative diseases. These techniques provide insights into the underlying biology, diagnostic classification, and treatment response across a broad spectrum of neurological conditions, encompassing Alzheimer's disease, frontotemporal lobar degeneration, Parkinson's disease, and beyond.
